News >

Targeted Agents, Immunotherapy Transforming Treatment Across NSCLC Spectrum

Caroline Seymour
Published: Thursday, Nov 14, 2019

Mark G. Kris, MD, medical oncologist, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center

Mark G. Kris, MD
Not only has osimertinib (Tagrisso) become the frontline standard of care for patients with EGFR-mutant non–small cell lung cancer (NSCLC), but it is a potent and tolerable agent to examine in combination as a way to prevent acquired resistance, said Mark G. Kris, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication